TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on May 28, 2013. The report addresses a corporate event regarding the listing of the Company's common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate listing event and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is the approval of the Company's common stock for listing on the NASDAQ Capital Market. The Company expects to commence trading under the ticker symbol "TGTX" on May 30, 2013.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies beyond the announcement of the stock listing. No unusual items were reported in this document.
Key Facts for Investor Verification
- Common stock approved for listing on the NASDAQ Capital Market.
- Trading expected to commence on May 30, 2013.
- New ticker symbol: "TGTX".
- Press release dated May 28, 2013, is attached as Exhibit 99.1.